Ahuva Nissim graduated in Molecular Immunology in 1992 from the Weizmann Institute of Science in Israel and was trained as a postdoctoral fellow at the MRC Centre for Protein Engineering in Cambridge until 1995. During this period she developed phage display semi-synthetic human antibody library which has been used worldwide. In November 2000 she was appointed as a Senior Lecturer at Queen Mary University. Her studies are interdisciplinary and involve translational research at the William Harvey Research Institute and with intensive worldwide collaborations. Her main research interest focuses on development of targeted immunotherapy, recently highlighted in Nature Review Rheumatology as a basis for development of novel therapy for arthritis (Nature Reviews Rheumatology 10, 511 (2014)
Summary of Research
The main research interest focuses on development of targeted immunotherapy to novel neoantigens produced specifically in diseased tissue. The role of free radicals in generation of neoantigens in inflammation is investigated. Hence, a specific targeted immunotherapy for the treatment of arthropathies has been developed. The research has expanded to other autoimmune condition such as periodontal diseases and type 1 diabetes. In addition, ongoing activities are on development of new repertoire as a source of new treatment modalities. Novel structural guided phage display human antibody libraries for development of human antibodies for clinical applications were developed.
Members of the Group
MD/PhD research fellow: Rocky Strollo (co-supervision with Prof Pozzilli as part of international collaboration with Campus Bio-Medico University of Rome)
Students: Chiara Vinci (with Prof Pozzilli), Valentino De Leo (in collaboration with Prof Roland Kontermann, University of Stuttgart)
Research staff: Dr Ngee Han Lim; Dr Angellica Sette
For a full list of publist publications click here
Targeting of viral interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves its therapeutic potency. Hughes C, Sette A, Seed M, D'Acquisto F, Manzo A, Vincent TL, Lim NH, Nissim A. Arthritis Res Ther. 2014 Jul 16;16(4):R151. doi: 10.1186/ar4613.
Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. Ryan BJ, Nissim A, Winyard PG. Redox Biol. 2014 May 28;2:715-24. doi: 10.1016/j.redox.2014.05.004. eCollection 2014.
Structural guided scaffold phage display libraries as a source of bio-therapeutics. Man YK, DiCara D, Chan N, Vessillier S, Mather SJ, Rowe ML, Howard MJ, Marshall JF, Nissim A. PLoS One. 2013 Aug 9;8(8):e70452. doi: 10.1371/journal.pone.0070452. eCollection 2013.
Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. Strollo R, Ponchel F, Malmström V, Rizzo P, Bombardieri M, Wenham CY, Landy R, Perret D, Watt F, Corrigall VM, Winyard PG, Pozzilli P, Conaghan PG, Panayi GS, Klareskog L, Emery P, Nissim A. Arthritis Rheum. 2013 Jul;65(7):1702-12. doi: 10.1002/art.37964
HLA-dependent autoantibodies against post-translationally modified collagen type II in type 1 diabetes mellitus. Strollo R, Rizzo P, Spoletini M, Landy R, Hughes C, Ponchel F, Napoli N, Palermo A, Buzzetti R, Pozzilli P, Nissim A. Diabetologia. 2012 Nov 19. [Epub ahead of print]
Involvement of autoimmunity in the pathogenesis of aggressive periodontitis. Hendler A, Mulli TK, Hughes FJ, Perrett D, Bombardieri M, Houri-Haddad Y, Weiss EI, Nissim A. J Dent Res. 2010 Dec;89(12):1389-94. Epub 2010 Oct 12
Human single-chain variable fragment that specifically targets arthritic cartilage. Hughes C, Faurholm B, Dell'Accio F, Manzo A, Seed M, Eltawil N, Marrelli A, Gould D, Subang C, Al-Kashi A, De Bari C, Winyard P, Chernajovsky Y, Nissim A. Arthritis Rheum. 2010 Apr;62(4):1007-16
Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed joint. Nissim A, Winyard PG, Corrigall V, Fatah R, Perrett D, Panayi G, Chernajovsky Y. Arthritis Rheum. 2005 Dec;52(12):3829-38
Historical development of monoclonal antibody therapeutics. Nissim A, Chernajovsky Y. Handb Exp Pharmacol. 2008;(181):3-18. Review.Dec;52(12):3829-38.